Comparing the current results to its competitors, Eledon Pharmaceuticals Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 7.8 %, recorded in the same quarter.
Eledon Pharmaceuticals Inc , slower than the average decrease reported by the company's competitors of -12.84 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -12.84 %
July 17, 2025
Eledon Pharmaceuticals: Navigating the Terrain of Kidney Transplant Research and Revenue ChallengesEledon Pharmaceuticals Inc., a biopharmaceutical company focusing on therapeutics for kidney transplant recipients, is currently making waves in the realm of clinical research. The company is advancing its Phase 1b trial of Tegoprubart, a novel therapy aimed at improving outcomes for patients undergoing kidney transplantation. As we prepare for the World Transplant Congress (WTC) 2025, the implications of Eledon s findings are significant, particularly as the industry grapples with market fluctuations and competitive pressures. Tegoprubart: A Potential Game-Changer in Kidney Transplantation Tegoprubart has sho...
September 4, 2024
Eledon Pharmaceuticals, a pioneering biotechnology company focused on advancing therapies for patients requiring organ transplants, has recently announced the successful completion of enrollment for its Phase 2 BESTOW clinical trial. This trial evaluates the efficacy of Tegoprubart in preventing organ rejection among kidney transplant patients, a critical area of need given the challenges that patients face post-transplantation. Tegoprubart is a distinct agent in the realm of transplant medicine. It is designed to modulate the immune system in a way that minimizes organ rejection, which is a significant concern following kidney transplants. The completion of patient enrollment in the BESTOW trial is seen as ...
June 3, 2024
Eledon Unveils Promising Data from Phase 1b Trial of Tegoprubart for Kidney Transplant Rejection Prevention Eledon Pharmaceuticals, a trailblazing biotech firm dedicated to innovative immunotherapeutic solutions, recently unveiled updated data from their ongoing Phase 1b clinical trial evaluating the efficacy of tegoprubart (formerly known as AT-1501) in the prevention of kidney transplant rejection. This new data augments the body of evidence underscoring the potential of tegoprubart as a pioneering therapeutic agent in the field of organ transplantation. The Burden of Rejection in Kidney Transplantation Kidney transplantation remains the gold standard treatment for patients suffering from end-stage renal d...
May 9, 2024
As major contributors in the field of clinical science and biopharmaceutical research, Eledon Pharmaceuticals continues to make considerable strides in the development of groundbreaking medications. At the forefront of their innovative endeavours is a dynamic compound known as Tegoprubart, which is currently under several phases of trial for its potential use in kidney transplant patients and as an aid in preventing organ rejection.In a recent press release, Eledon Pharmaceuticals announced that they will present updated data results from their ongoing Phase 1b Trial of Tegoprubart at this year s prestigious American Transplant Congress (ATC). This yearly gathering of scholars and professionals in the transp...
March 25, 2024
Organ transplants have the potential to save countless lives, yet the risk of organ rejection continues to pose a significant challenge in post-transplant care. In an exciting development, Eledon Pharmaceuticals recently announced the enrollment of their 12th participant in the Phase 2 BESTOW Trial, which evaluates the efficacy and safety of their groundbreaking drug, Tegoprubart, in preventing organ rejection. This article delves into the novel approach of Tegoprubart, its potential for revolutionizing transplant medicine, and the significance of the ongoing BESTOW Trial.Understanding Organ Rejection:Organ transplantation is a life-saving procedure that aims to replace deteriorated or dysfunctional organs w...
Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.
Sources:
Eledon Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Eledon Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
